Noteworthily, clinical trials targeting PVR and its interactions are either antibodies directed against TIGIT in combination with other mAbs or chemotherapy or radiation (refer to TIGIT section) or use PVR as a point of entry for recombinant oncolytic polioviruses in the case of advanced gliomas (NCT01491893, NCT03043391, and NCT02986178) or triple negative breast cancer (NCT03564782)9. The gene discussed is PVR; the disease is triple-negative breast carcinoma.